AQUATENSEN Drug Patent Profile
✉ Email this page to a colleague
When do Aquatensen patents expire, and when can generic versions of Aquatensen launch?
Aquatensen is a drug marketed by Medpointe Pharm Hlc and is included in one NDA.
The generic ingredient in AQUATENSEN is methyclothiazide. There are two drug master file entries for this compound. Additional details are available on the methyclothiazide profile page.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for AQUATENSEN?
- What are the global sales for AQUATENSEN?
- What is Average Wholesale Price for AQUATENSEN?
Summary for AQUATENSEN
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 68 |
| Patent Applications: | 4,202 |
| DailyMed Link: | AQUATENSEN at DailyMed |
US Patents and Regulatory Information for AQUATENSEN
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Medpointe Pharm Hlc | AQUATENSEN | methyclothiazide | TABLET;ORAL | 017364-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Subscribe | ⤷ Subscribe | ⤷ Subscribe | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
